Logo
Menu

Delivering a complete breast cancer solution for you and your patients

Trust the experts with over 20 years of experience. 

Tests & services
Tests & services

In the United States, 1 in 8 women will be diagnosed with invasive breast cancer.1

As the #1 lab in breast cancer testing with over 20 years of expertise, NeoGenomics offers a comprehensive suite of tests to support the entire breast cancer care continuum. From diagnosis to therapy selection, prognosis, and clinical trial options, NeoGenomics provides the expertise and precision needed at every stage of breast cancer care.

Featured breast cancer solutions

Neo Comprehensive - Solid Tumor

NGS comprehensive genomic profile targeting 517 genes in DNA and RNA for SNVs, InDels, CNVs, RNA fusions/splice variants with MSI and TMB for pan-solid tumors.

8-10 Days turnaround time

Learn more about this test

Breast Cancer Index® (BCI)

MGMT (O-6-methylguanine-DNA methyltransferase) is a DNA repair enzyme. MGMT protects cells from alkylating toxins, and is an important factor in drug resistance to alkylating therapeutic agents.

7 to 10 Days turnaround time

Learn more about this test

Comprehensive testing for metastatic breast cancer patients

As the precision medicine landscape for metastatic breast cancer (mBC) patients evolves, so does the need for biomarker testing. Clinical practice guidelines now recommend biomarker testing for all metastatic breast cancer patients, regardless of subtype. The NeoGenomics breast cancer solution provides comprehensive genomic profiling to help inform treatment decisions and clinical trial availability for mBC patients.

Clinically actionable biomarkers for breast cancer2-4

breast biomarkers

MSI, microsatellite instability; TMB, tumor mutation burden.

Add-on testing for therapy selection

PD-L1 22C3 FDA (KEYTRUDA®) for TNBC (Breast)

Global: 2 Day, Tech-Only (stain only): 1 Day turnaround time

Learn more about this test

HER2 Breast

Global: 2 Day, Image Analysis (Tech-Only): 2 Day, Tech-Only (stain only): 1 Day turnaround time

Learn more about this test

References

  1. Menon G, Alkabban FM, Ferguson T. Breast cancer. StatPearls [Internet]. StatPearls Publishing. Last updated February 25, 2024. Accessed December 23, 2024. https://www.ncbi.nlm.nih.gov/books/NBK482286/

  2. Suehnholz SP, Nissan MH, Zhang H, et al. Quantifying the expanding landscape of clinical actionability for patients with cancer. Cancer Discov. 2024;14(1):49-65.

  3. Chakravarty D, Gao J, Phillips S, et al. OncoKB: A precision oncology knowledge base. JCO Precis Oncol. 2017;2017:PO.17.00011.

  4. Al Sukhun S, Temin S, Barrios CH, et al. Systemic treatment of patients with metastatic breast cancer: ASCO resource-stratified guideline. JCO Glob Oncol. 2024;10:e2300285.

Still have questions?

We pride ourselves on our unparalleled Client Services team. If you have questions regarding test information, specimen requirements, turnaround times, test add-ons, or patient results, please email us at client.services@neogenomics.com or call 866.776.5907, Option 3.